GlassScriptPhysician profile
Yan Lin
NPI 1831677178
$7,534.86
in general payments reported to CMS, 2019-2025
42 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $892 · 2023: $2,050 · 2024: $1,681 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,823 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,823.10 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,591.25 | 2022-2025 | Vemlidy, Livdelzi, Trodelvy |
| Astrazeneca Pharmaceuticals LP | $980.62 | 2021-2025 | Farxiga, Airsupra, Tagrisso |
| Amgen INC. | $943.53 | 2021-2025 | Otezla, Repatha, Repatha |
| Janssen Biotech, INC. | $356.63 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Eisai INC. | $321.74 | 2021-2025 | |
| Novo Nordisk INC | $313.97 | 2021-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $313.75 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $267.17 | 2022-2025 | Verzenio, Jaypirca, Mounjaro |
| Novartis Pharmaceuticals Corporation | $204.22 | 2023-2024 | |
| Astellas Pharma US INC | $184.56 | 2023-2024 | Xtandi, Xospata |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.58 | 2022-2025 | Jardiance, Gilotrif |
| Medtronic, INC. | $178.45 | 2025 | Symplicity G3 |
| Incyte Corporation | $164.25 | 2021-2023 | Monjuvi, Pemazyre, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $156.43 | 2022-2025 | |
| Intuitive Surgical, INC. | $123.45 | 2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $115.04 | 2024 | Cologuard Collection Kit |
| Puma Biotechnology, INC. | $97.31 | 2021-2024 | Nerlynx |
| Takeda Pharmaceuticals U.S.A., INC. | $71.47 | 2023-2025 | Ninlaro |
| Seagen INC. | $70.87 | 2021-2023 | Tukysa, Padcev |
| Madrigal Pharmaceuticals | $67.49 | 2024-2025 | Resmetirom, Rezdiffra |
| Abbvie INC. | $66.42 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $65.30 | 2021-2024 | Camzyos |
| Rigel Pharmaceuticals, INC. | $53.08 | 2024 | Tavalisse, Rezlidhia |
| Recordati_rare_diseases_inc. | $52.86 | 2025 | Sylvant |
| Foundation Medicine, INC. | $48.13 | 2023 | |
| Amarin Pharma, INC. | $48.07 | 2022-2023 | |
| Myovant Sciences INC. | $46.64 | 2021 | |
| Taiho Oncology, INC. | $46.59 | 2024 | |
| Sumitomo Pharma America, INC. | $43.35 | 2023 | Orgovyx |
| Genzyme Corporation | $43.17 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $42.87 | 2021-2023 | Libtayo |
| Dova Pharmaceuticals | $36.23 | 2021 | |
| Pfizer INC. | $34.27 | 2021-2025 | |
| Pharmaessentia USA Corporation | $30.48 | 2024 | Besremi |
| Emd Serono, INC. | $26.13 | 2023 | Tepmetko |
| Genmab U.S., INC. | $23.51 | 2024 | Epkinly |
| Sobi, INC | $23.30 | 2025 | |
| Stemline Therapeutics INC. | $21.08 | 2023 | Orserdu |
| Esperion Therapeutics, INC. | $20.00 | 2021 | |
| Myriad Genetic Laboratories, INC. | $20.00 | 2021 | |
| Glaxosmithkline, LLC. | $19.62 | 2024 | Trelegy Ellipta |
| Mirati Therapeutics, INC. | $17.98 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.